Regulatory Clarity and a Billion-Dollar Buyback: BioNTech’s Twin Catalysts Emerge from ASCO

BioNTech left the ASCO oncology conference with more than just clinical data sheets. The Mainz-based biotech secured a regulatory roadmap for its lead candidate Pumitamig and simultaneously unveiled a $1 billion share buyback programme, sending the stock 2.68% higher on Friday to close at €82.35 on XETRA. Yet the shares remain roughly flat year-to-date and hover about 19% below their 52-week peak of €101.90, underscoring the tug-of-war between pipeline promise and the cost of transformation.

Pumitamig, a bispecific antibody that blocks both PD-L1 and VEGF-A, delivered response rates that surprised even bullish observers. In the Phase 2 ROSETTA Lung-02 study conducted with partner Bristol Myers Squibb, the confirmed overall response rate (cORR) for squamous non-small cell lung cancer patients reached 68.4% when combined with chemotherapy, and 57.1% in the non-squamous cohort. At the lower 1,400 mg dose, the figures climbed to 72.7% and 63.6%, respectively. Across all 40 evaluable patients, the disease control rate hit 100%, with those expressing high PD-L1 (TPS ?50%) showing complete responses. Even in the PD-L1-negative subgroup, the cORR stood at 47.6%. Safety was within expected ranges: grade 3 or higher adverse events occurred in 48.8% of patients, and only 9.3% discontinued treatment due to side effects.

On the regulatory front, BioNTech and BMS have aligned with the FDA on a clear path to market. The partners have designated progression-free survival as the primary endpoint for the ongoing Phase 3 trial, with overall survival as a secondary measure. Because PFS data mature faster, this opens the door to an accelerated approval filing. To ensure statistical power, the Phase 3 study has been expanded to roughly 1,260 patients. UBS, which upgraded the stock to Buy on May 27 and raised its price target to $135 from $117, specifically cited this pipeline strength as a catalyst.

Should investors sell immediately? Or is it worth buying BioNTech?

Not all analysts share the same conviction. While Canaccord Genuity, UBS and Wells Fargo issued buy recommendations, Bernstein held at "Market Perform". The average price target from 17 analysts sits at approximately €107, implying a 30% upside from current levels. The relative strength index of 53 places the stock in neutral territory, reflecting the market’s wait-and-see posture.

BioNTech’s financial position gives it the firepower to pursue its oncology ambitions. The company ended March with €16.8 billion in cash and marketable securities, of which €13.71 billion is considered immediately available liquidity. Yet the numbers also highlight the cost of the pivot: first-quarter revenue slumped to just €118.1 million, producing an operating deficit of €494.6 million and a net loss of €531.9 million. Management maintained its full-year revenue guidance of €2 billion to €2.3 billion. The new $1 billion buyback programme is intended to signal confidence during this expensive transition from a Covid-19 vaccine powerhouse to an oncology-focused drugmaker.

Looking ahead, six late-stage clinical readouts are scheduled for the remainder of 2026, and the next major milestone is the second-quarter earnings report due on August 4. For BioNTech’s shares, the question remains whether the depth of the pipeline can close the gap between current valuation and the consensus target — or whether the market will demand more proof before pricing in the oncology thesis.

Ad

BioNTech Stock: New Analysis - 31 May

Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated BioNTech analysis...

en | US09075V1026 | REGULATORY | boerse | 69457538 |